IL17A and psoriasis: Case reports from Italy have shown that patients with a history of psoriasis and previous treatment with IL-17A antagonists including secukinumab and ixekizumab showed relatively mild COVID-19 symptoms or were even asymptomatic.290–292 A retrospective, observational, multicenter clinical trial from Italy containing 5206 patients with psoriasis who have been prescribed medications including IL-17 inhibitors showed that only four patients were hospitalized for COVID-19, and no deaths occurred,293 indicating the protective role of IL-17A inhibitors in COVID-CS and ARDS.